NASDAQ:ADMA ADMA Biologics (ADMA) Stock Forecast, Price & News $4.06 0.00 (0.00%) (As of 06/7/2023 ET) Add Compare Share Share Today's Range$4.00▼$4.1050-Day Range$3.12▼$4.2252-Week Range$1.85▼$4.30Volume1.54 million shsAverage Volume2.37 million shsMarket Capitalization$902.43 millionP/E RatioN/ADividend YieldN/APrice Target$5.25 ProfileProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial Media ADMA Biologics MarketRank™ ForecastAnalyst RatingBuy3.00 Rating ScoreUpside/Downside29.3% Upside$5.25 Price TargetShort InterestBearish5.03% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment-0.14Based on 5 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($0.09) to $0.07 Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.1.95 out of 5 starsMedical Sector560th out of 981 stocksBiological Products, Except Diagnostic Industry88th out of 159 stocks 3.5 Analyst's Opinion Consensus RatingADMA Biologics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $5.25, ADMA Biologics has a forecasted upside of 29.3% from its current price of $4.06.Amount of Analyst CoverageADMA Biologics has received no research coverage in the past 90 days. Previous Next 2.0 Short Interest Percentage of Shares Shorted5.03% of the outstanding shares of ADMA Biologics have been sold short.Short Interest Ratio / Days to CoverADMA Biologics has a short interest ratio ("days to cover") of 4.6.Change versus previous monthShort interest in ADMA Biologics has recently decreased by 1.24%, indicating that investor sentiment is improving. Previous Next 0.0 Dividend Strength Dividend YieldADMA Biologics does not currently pay a dividend.Dividend GrowthADMA Biologics does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for ADMA. Previous Next 2.1 News and Social Media Coverage News SentimentADMA Biologics has a news sentiment score of -0.14. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.51 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 5 news articles for ADMA Biologics this week, compared to 3 articles on an average week.Search Interest32 people have searched for ADMA on MarketBeat in the last 30 days. This is an increase of 1,500% compared to the previous 30 days.MarketBeat Follows5 people have added ADMA Biologics to their MarketBeat watchlist in the last 30 days. This is an increase of 25% compared to the previous 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, ADMA Biologics insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 5.90% of the stock of ADMA Biologics is held by insiders.Percentage Held by Institutions71.17% of the stock of ADMA Biologics is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for ADMA Biologics are expected to grow in the coming year, from ($0.09) to $0.07 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of ADMA Biologics is -16.92, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of ADMA Biologics is -16.92, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioADMA Biologics has a P/B Ratio of 5.88. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About ADMA Biologics (NASDAQ:ADMA) StockADMA Biologics, Inc. operates as a biopharmaceutical company, which is engaged in manufacturing, marketing, and developing specialty plasma-derived biologics. The firm operates through the following business segments: ADMA BioManufacturing, Plasma Collection Center, and Corporate. The ADMA BioManufacturing segment consists of immune globulin manufacturing and development operations. The Plasma Collection Center consists of source plasma collection facilities. The Corporate segment includes general and administrative overhead expenses. The company was founded by Adam S. Grossman and Jerrold B. Grossman on June 24, 2004 and is headquartered in Ramsey, NJ.Read More Receive ADMA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for ADMA Biologics and its competitors with MarketBeat's FREE daily newsletter. Email Address ADMA Stock News HeadlinesJune 5, 2023 | finance.yahoo.comBristol Myers (BMY) Announces Upbeat Data From NSCLC StudyJune 5, 2023 | finance.yahoo.comBioNTech (BNTX) Up on Initial Data From Lung Cancer AntibodyJune 8, 2023 | Edge On The Street (Ad)The Real Problem With "Made in America" LithiumPoliticians love to say they support "Made in America" when it comes to manufacturing. But when it comes to lithium - the metal fueling our transition to electric vehicles - it's not that simple. June 2, 2023 | americanbankingnews.comADMA Biologics (NASDAQ:ADMA) Lowered to Sell at StockNews.comJune 1, 2023 | msn.comAridis (ARDS) Up After FDA Nod for Pneumonia Drug Study DesignMay 30, 2023 | finance.yahoo.comLexicon's (LXRX) Heart Failure Drug Inpefa Gets FDA ApprovalMay 29, 2023 | finance.yahoo.comAre Medical Stocks Lagging ADMA Biologics (ADMA) This Year?May 26, 2023 | finance.yahoo.comPlasma Derived Therapies Global Market to 2027: Increasing Prevalence of Genetic Disorders Drives GrowthJune 8, 2023 | Edge On The Street (Ad)The Real Problem With "Made in America" LithiumPoliticians love to say they support "Made in America" when it comes to manufacturing. But when it comes to lithium - the metal fueling our transition to electric vehicles - it's not that simple. May 25, 2023 | finance.yahoo.comImmutep (IMMP) Up on Initial Data From Lung Cancer StudyMay 22, 2023 | finance.yahoo.comKrystal's (KRYS) Dermatology Drug Gets FDA Nod, Stock Up 10%May 19, 2023 | americanbankingnews.comADMA Biologics (NASDAQ:ADMA) Coverage Initiated by Analysts at StockNews.comMay 17, 2023 | finance.yahoo.comADMA Biologics (NASDAQ:ADMA) rallies 18% this week, taking one-year gains to 102%May 16, 2023 | americanbankingnews.comADMA Biologics, Inc. (NASDAQ:ADMA) to Post Q2 2023 Earnings of ($0.02) Per Share, HC Wainwright ForecastsMay 13, 2023 | americanbankingnews.comADMA Biologics (NASDAQ:ADMA) Shares Gap Up to $3.57May 13, 2023 | americanbankingnews.comTraders Purchase High Volume of Call Options on ADMA Biologics (NASDAQ:ADMA)May 12, 2023 | finance.yahoo.comIs ADMA Biologics (ADMA) Stock Outpacing Its Medical Peers This Year?May 11, 2023 | finanznachrichten.deADMA Biologics, Inc.: ADMA Biologics Announces First Quarter 2023 Financial Results and Provides Business UpdateMay 11, 2023 | marketwatch.com10-Q: ADMA BIOLOGICS, INC.May 11, 2023 | finance.yahoo.comQ1 2023 ADMA Biologics Inc Earnings CallMay 10, 2023 | finance.yahoo.comADMA Biologics Announces First Quarter 2023 Financial Results and Provides Business UpdateMay 9, 2023 | americanbankingnews.comADMA Biologics (ADMA) Scheduled to Post Quarterly Earnings on WednesdayMay 4, 2023 | americanbankingnews.comADMA Biologics, Inc. (NASDAQ:ADMA) Short Interest UpdateMay 3, 2023 | finance.yahoo.comADMA Biologics to Report First Quarter 2023 Financial Results on May 10, 2023May 2, 2023 | finance.yahoo.comADMA Biologics Announces Amendment to Credit AgreementApril 30, 2023 | americanbankingnews.comADMA Biologics (NASDAQ:ADMA) Stock Price Crosses Below Two Hundred Day Moving Average of $3.31April 28, 2023 | marketwatch.comPlasma Therapeutics Market Size By 2030See More Headlines ADMA Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart ADMA Company Calendar Last Earnings3/23/2023Today6/08/2023Next Earnings (Estimated)8/09/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Biological products, except diagnostic Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:ADMA CUSIPN/A CIK1368514 Webwww.admabiologics.com Phone(201) 478-5552Fax201-478-5553Employees527Year FoundedN/APrice Target and Rating Average Stock Price Forecast$5.25 High Stock Price Forecast$6.00 Low Stock Price Forecast$4.50 Forecasted Upside/Downside+29.3%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage2 Analysts Profitability EPS (Most Recent Fiscal Year)($0.24) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-65,900,000.00 Net Margins-26.22% Pretax Margin-26.22% Return on Equity-37.22% Return on Assets-14.82% Debt Debt-to-Equity Ratio1.06 Current Ratio7.19 Quick Ratio2.73 Sales & Book Value Annual Sales$181.89 million Price / Sales4.96 Cash FlowN/A Price / Cash FlowN/A Book Value$0.69 per share Price / Book5.88Miscellaneous Outstanding Shares222,273,000Free Float209,159,000Market Cap$902.43 million OptionableOptionable Beta0.90 Key ExecutivesAdam S. GrossmanPresident, Chief Executive Officer & DirectorAtkinson VernonOperations DirectorBrian LenzChief Financial Officer & Executive Vice PresidentKaitlin KestenbergVice President-Compliance & Clinical OperationsLucy DeMarioSenior Director-Scientific & Data AnalysisKey CompetitorsValnevaNASDAQ:VALNREGENXBIONASDAQ:RGNXAllogene TherapeuticsNASDAQ:ALLOTwist BioscienceNASDAQ:TWSTImmaticsNASDAQ:IMTXView All CompetitorsInsiders & InstitutionsJPMorgan Chase & Co.Sold 110,684 shares on 5/18/2023Ownership: 0.078%New York State Common Retirement FundSold 37,727 shares on 5/18/2023Ownership: 0.041%Fred Alger Management LLCSold 10,773 shares on 5/16/2023Ownership: 0.908%AQR Capital Management LLCBought 16,463 shares on 5/16/2023Ownership: 0.063%Alberta Investment Management CorpBought 22,273 shares on 5/16/2023Ownership: 0.010%View All Insider TransactionsView All Institutional Transactions ADMA Stock - Frequently Asked Questions Should I buy or sell ADMA Biologics stock right now? 2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for ADMA Biologics in the last twelve months. There are currently 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" ADMA shares. View ADMA analyst ratings or view top-rated stocks. What is ADMA Biologics' stock price forecast for 2023? 2 brokerages have issued 12-month price targets for ADMA Biologics' shares. Their ADMA share price forecasts range from $4.50 to $6.00. On average, they anticipate the company's share price to reach $5.25 in the next twelve months. This suggests a possible upside of 29.3% from the stock's current price. View analysts price targets for ADMA or view top-rated stocks among Wall Street analysts. How have ADMA shares performed in 2023? ADMA Biologics' stock was trading at $3.88 at the start of the year. Since then, ADMA stock has increased by 4.6% and is now trading at $4.06. View the best growth stocks for 2023 here. When is ADMA Biologics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Wednesday, August 9th 2023. View our ADMA earnings forecast. How were ADMA Biologics' earnings last quarter? ADMA Biologics, Inc. (NASDAQ:ADMA) issued its quarterly earnings results on Thursday, March, 23rd. The biotechnology company reported ($0.06) EPS for the quarter, meeting the consensus estimate of ($0.06). The biotechnology company earned $49.98 million during the quarter, compared to the consensus estimate of $49.02 million. ADMA Biologics had a negative net margin of 26.22% and a negative trailing twelve-month return on equity of 37.22%. During the same period in the prior year, the business earned ($0.09) EPS. What ETFs hold ADMA Biologics' stock? ETFs with the largest weight of ADMA Biologics (NASDAQ:ADMA) stock in their portfolio include Virtus LifeSci Biotech Products ETF (BBP), Inspire Fidelis Multi Factor ETF (FDLS), Invesco Raymond James SB-1 Equity ETF (RYJ), SPDR S&P Biotech ETF (XBI), Direxion Daily S&P Biotech Bull 3x Shares (LABU), Principal Healthcare Innovators ETF (BTEC), iShares Micro-Cap ETF (IWC) and Vanguard U.S. Momentum Factor ETF (VFMO). What guidance has ADMA Biologics issued on next quarter's earnings? ADMA Biologics updated its FY 2025 earnings guidance on Friday, May, 12th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $300.00M-. What is Adam S. Grossman's approval rating as ADMA Biologics' CEO? 9 employees have rated ADMA Biologics Chief Executive Officer Adam S. Grossman on Glassdoor.com. Adam S. Grossman has an approval rating of 29% among the company's employees. This puts Adam S. Grossman in the bottom 10% of approval ratings compared to other CEOs of publicly-traded companies. What other stocks do shareholders of ADMA Biologics own? Based on aggregate information from My MarketBeat watchlists, some companies that other ADMA Biologics investors own include Matinas BioPharma (MTNB), Pennsylvania Real Estate Investment Trust (PEI), Organigram (OGI), Gran Tierra Energy (GTE), Tilly's (TLYS), Bionano Genomics (BNGO), Novan (NOVN), CNBX Pharmaceuticals (CNBX), Zosano Pharma (ZSAN) and DHT (DHT). What is ADMA Biologics' stock symbol? ADMA Biologics trades on the NASDAQ under the ticker symbol "ADMA." Who are ADMA Biologics' major shareholders? ADMA Biologics' stock is owned by a number of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (7.38%), State Street Corp (5.85%), Stonepine Capital Management LLC (3.45%), Assenagon Asset Management S.A. (3.00%), Geode Capital Management LLC (1.82%) and Two Sigma Investments LP (1.04%). Insiders that own company stock include Adam S Grossman, Adam S Grossman, Brian Lenz, James Mond, Jerrold B Grossman, Perceptive Advisors Llc and Young Kwon. View institutional ownership trends. How do I buy shares of ADMA Biologics? Shares of ADMA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is ADMA Biologics' stock price today? One share of ADMA stock can currently be purchased for approximately $4.06. How much money does ADMA Biologics make? ADMA Biologics (NASDAQ:ADMA) has a market capitalization of $902.43 million and generates $181.89 million in revenue each year. The biotechnology company earns $-65,900,000.00 in net income (profit) each year or ($0.24) on an earnings per share basis. How many employees does ADMA Biologics have? The company employs 527 workers across the globe. How can I contact ADMA Biologics? ADMA Biologics' mailing address is 465 STATE ROUTE 17, RAMSEY NJ, 07446. The official website for the company is www.admabiologics.com. The biotechnology company can be reached via phone at (201) 478-5552, via email at info@admabio.com, or via fax at 201-478-5553. This page (NASDAQ:ADMA) was last updated on 6/8/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding ADMA Biologics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.